Strategic Use of Bispecific Antibodies in R/R MM
Panelists discuss at what line of therapy bispecific antibodies are considered in treatment decision-making, whether they are used earlier or later in the sequence, and the factors influencing that choice, including weighing bispecifics against other options like chimeric antigen receptor (chimeric antigen receptor) T or standard therapies. They also address the clinical and molecular factors that guide the selection between B-cell maturation antigen (BCMA)– and GPRC5D-targeting bispecifics and comment on the study exploring talquetamab as a bridging strategy before BCMA CAR T therapy, highlighting the potential impact of bispecifics in this treatment paradigm.
Video content above is prompted by the following:
- At what line of therapy do you consider bispecific antibodies in your treatment decision-making? Are you using them earlier or later in the treatment sequence, and what factors influence that decision?
- How do you weigh bispecific antibodies against other treatment options like CAR T or other standard therapies?
- What clinical and molecular factors do you prioritize when choosing between BCMA- and GPRC5D-targeting bispecifics?
- Please comment on this study looking at talquetamab as a bridging strategy before BCMA CAR T-cell therapy, and the potential impact of bispecifics in this treatment paradigm
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
